Hepatic Cell News Volume 4.34 | Sep 11 2020

    0
    29







    HCN 4.34 | 2020-09-11


    Hepatic Cell News by STEMCELL Technologies
    Vol. 4.34 – 11 September, 2020
    TOP STORY

    TREM-2
    Defends the Liver against Hepatocellular Carcinoma through Multifactorial Protective Mechanisms

    TREM-2 expression was analyzed in liver tissues of two independent cohorts of patients with hepatocellular carcinoma (HCC) and compared with control liver samples. Experimental HCC and liver regeneration models in wild type and Trem-2-/- mice, and in vitro studies with hepatic stellate cells and HCC spheroids were conducted.
    [Gut]

    Full Article


    In this webinar on hepatic organoids review the biological characteristics and practical considerations of adding organoids to your research.
    PUBLICATIONSRanked by the impact factor of the journal

    RSK2-Inactivating
    Mutations Potentiate MAPK Signaling and Support Cholesterol Metabolism in Hepatocellular Carcinoma

    Investigators detected recurrent somatic p90 Ribosomal S6 kinase 2 (RSK2) mutations at a rate of 6.3% in hepatocellular carcinoma (HCC) cohorts, and revealed that HCC was the top-ranking cancer harboring RSK2 mutations among many cancer types.
    [Journal of Hepatology]

    AbstractGraphical Abstract

    Purification
    of HCC-Specific Extracellular Vesicles on Nanosubstrates for Early HCC Detection by Digital Scoring

    Scientists developed an hepatocellular carcinoma (HCC) extracellular vesicle (EV) purification system by synergistically integrating covalent chemistry-mediated EV capture/release, multimarker antibody cocktails, nanostructured substrates, and microfluidic chaotic mixers.
    [Nature Communications]

    Full Article

    Hepatic
    MiR-192-3p Re-Activation Alleviates Steatosis by Targeting Glucocorticoid Receptor

    Hepatocytes overexpressing miR-192-3p exhibited improved lipid accumulation, accompanied with decreases in lipogenesis and lipid accumulation-related transcripts.
    [JHEP Reports]

    Full ArticleGraphical Abstract

    Bromodomain-Containing
    Protein 9 Promotes the Growth and Metastasis of Human Hepatocellular Carcinoma by Activating the TUFT1/AKT Pathway

    Bromodomain-containing protein 9 (BRD9) expression was found to be elevated in hepatocellular carcinoma (HCC) through data mining of public databases. Scientists confirmed that the expression of BRD9 was increased in HCC tissues compared with that in adjacent non-tumor tissues. The upregulated level of BRD9 was also observed in HCC cells in comparison to LO2 cells.
    [Cell Death & Disease]

    Full Article

    Selective
    Inhibition of CBP/p300 HAT by A-485 Results in Suppression of Lipogenesis and Hepatic Gluconeogenesis

    In primary mouse hepatocytes, A-485 abolished cAMP-elicited mRNA expressions of key gluconeogenic enzymes and promoted FOXO1 protein degradation via increasing its ubiquitination.
    [Cell Death & Disease]

    Full Article

    Tyrosine
    Kinase Inhibitor Neratinib Attenuates Liver Fibrosis by Targeting Activated Hepatic Stellate Cells

    Researchers elucidated the anti-fibrotic effects of neratinib in hepatic stellate cells (HSCs) and in vivo models of CCl4-induced liver fibrosis. HSC activation was a key step in liver fibrogenesis and played a crucial role in collagen deposition, as it is primarily responsible for excessive ECM production.
    [Scientific Reports]

    Full Article

    The
    Loss of Nuclear PTEN Increases Tumorigenesis in a Preclinical Mouse Model for Hepatocellular Carcinoma

    Using nuclear PTEN-deficient mice, scientists analyzed the role of PTEN in the nucleus in hepatocellular carcinoma that was induced by carcinogen and oxidative-stress producing hepatotoxin.
    [iScience]

    AbstractFull Article

    Group 2 Innate Lymphoid Cells Exacerbate Amebic Liver Abscess in Mice

    Researchers examined the roles of group 2 innate lymphoid cells (ILC2s) in amebic liver abscesses formation. Hepatic ILC2 numbers were significantly increased and they produced robust levels of IL-5.
    [iScience]

    AbstractGraphical Abstract


    Virtual Conference Exhibition: Pluripotent Stem Cells
    REVIEWS

    The Times They are A-Changin’ (For NAFLD as well)

    Diseases like non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) bring a very high level of pathogenic complexity and far-reaching implications that apply not only scientists but also to clinicians, patients, regulators, bio-pharmaceutical industry and third-party payers.
    [Journal of Hepatology]

    Full Article

    The
    Emerging Role of Long Noncoding RNAs in Normal Liver Function, Disease and Malignancy

    Investigators summarize current understanding of the function of lncRNAs in the liver in both health and disease and discuss approaches that could be used to target these noncoding transcripts for therapeutic purposes.
    [JHEP Reports]

    Full Article

    Bisphosphonates and Risk of Cancers: A Systematic Review and Meta-Analysis

    The authors aimed to evaluate the effect of bisphosphonates on overall cancers. They note that non-nitrogen-containing bisphosphonates might increase the risk of liver and pancreas cancer. Large prospective cohort studies are needed to find the causal association between bisphosphonates and risk of cancers.
    [British Journal of Cancer]

    Full Article

    INDUSTRY AND POLICY NEWS

    Theratechnologies to Develop Tesamorelin for the Treatment of NASH in the General Population

    Theratechnologies Inc. has announced that it plans to pursue Phase III clinical development of tesamorelin for the treatment of non-alcoholic steatohepatitis (NASH) in the general population.
    [Theratechnologies Inc. (GloveNewswire Inc.)]

    Press Release

    FEATURED EVENT

    Cell Biology 2020

    Sep 23
    Virtual


    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellow – Stem Cells and Organoid Biology

    Max-Planck Center for Tissue Stem Cell Research and Regenerative Medicine – Guangzhou, China or Maine, United States

    Associate
    Scientist – Metabolic Dysfunction

    Temple University Medical School – Philadelphia, Pennsylvania, United States

    Postdoctoral
    Scientist – Molecular Biology, Virology or Immunology

    Texas Biomedical Research Institute – San Antonio, Texas, United States

    Scientific
    Researcher – Virology

    Institute for Virology, University Hospital Cologne – Cologne, Germany

    Postdoctoral Scientist – Infectious Diseases

    Texas Biomedical Research Institute – San Antonio, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Hepatic Cell News
    Archives Contact Us
    Hepatic Cell News Twitter